Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.

Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.

The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases.

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation.

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.

Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.

The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

Konstanz molecular biologist Elke Deuerling has been admitted to the German National Academy of Sciences, the "Leopoldina". By selecting Elke Deuerling as a member, the Academy recognizes her outstanding contributions to the field of life sciences, particularly to proteostasis research.

The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress alternative cell programs.

Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

Within biological cells, molecules are constantly in motion. Investigating these motions, however, is still difficult, due to the fact that these processes occur on very small length and time scales. To overcome these challenges, researchers from HITS and MPI-P have developed a simulation method that works rapidly and can predict chemical processes in cells with high precision. Their findings have been published in Nature Communications.

Not only actual chronological age, but also individual aging at the molecular level is a key factor in the development of cancer. This was discovered by scientists at the DKFZ and the Saarland Cancer Registry. If the so-called “epigenetic clocks” indicate accelerated biological aging, the likelihood of a cancer diagnosis increases. This finding could help identify at-risk groups and make early detection screenings more targeted

SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows.

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.

Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning.

Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning.

Proof-of-concept study of organoid technology - 26/03/2026

Can organoids improve the treatment of pancreatic cancer?

A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.

For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

Traumatic brain injuries often lead to complications with long-lasting consequences on memory, concentration and movement control. Detrimental secondary inflammatory reactions at the injured tissue sites are often responsible for this. Researchers from Ulm have now shown that a transcription factor plays a key role in reactions to TBI. When this gene regulator is activated, an elevated neuroimmune response promotes inflammation.

In the earliest phase of creating human proteins, the protein complex NAC performs an essential task by starting the first steps towards folding proteins into their correct three-dimensional structures. This discovery was made by an international research team led by scientists from the Center for Molecular Biology of Heidelberg University.

The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells.

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.

The powerhouse of the cells, known as mitochondria, appear to be able to influence the number of lipid droplets in the cell. Research into this previously unknown mechanism was conducted using baker’s yeast. This is shown by a recent study by the University of Freiburg, the University of Bonn and the University Hospital Bonn and the University of Freiburg. The results have now been published in the journal Nature Cell Biology.

Technology impulse for the Lake Constance region: The new Single Cell Centre at the University of Konstanz offers technology and expertise to study cells individually and at high resolution – for applications in medical diagnostics, medication development and basic research at universities.

Alithea Biotechnology GmbH - 12/02/2026

Intelligent immunotherapy – safety ensured

Immunological cell fingerprints are Alithea Bio’s core expertise. The Freiburg-based company combines advanced molecular biology with cutting-edge IT and operates one of the world’s largest immunopeptidomics databases. Alithea Bio leverages this integrated platform to offer both contract research services and software-as-a-service solutions to develop safer and more precise personalised immunotherapies more quickly.

Rewriting the transcript to heal diseases - 29/01/2026

Therapy involving the umlauts of the genetic alphabet

tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

Artificial intelligence allows tracing the evolution of genetic control elements in the developing mammalian cerebellum. An international research team led by biologists from Heidelberg University as well as the Vlaams Instituut voor Biotechnologie and KU Leuven has now developed advanced AI models that can predict the activity of these elements based solely on their DNA sequence.

To ensure that protein production in our cells runs smoothly, the protein complex NAC slows down the rate of protein synthesis right at the start. An international research team with significant involvement of Konstanz biologists has now discovered what underlies this previously unknown function of NAC.

Inside cells, RNAs and proteins form biomolecular condensates. These droplets are essential for organizing cellular life, yet why some RNAs cluster more readily than others has remained unclear. Disruptions in condensate formation are linked to developmental defects, cancer, and neurodegenerative diseases. Researchers at KIT have now identified a new class of RNA called smOOPs and gained a better understanding of how biomolecular condensates form

Heidelberg University has been successful in the current approval round of the German Research Foundation (DFG) with three grant applications for major research consortia. In the life sciences and medicine, a Collaborative Research Centre working on the Wnt signaling pathway will enter its third funding period. Two transregional consortia with major participation by researchers from Ruperto Carola have also been extended.

In the current selection round, the German Research Foundation (DFG) has granted funding for two new Collaborative Research Centres at the University of Konstanz. Over the next four years, the research teams will be working intensively on trigger signals in biological cells as well as on "silence" and "noise" in human speech.

Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging. The scientist from the DKFZ-Hector Cancer Institute is the winner of the Falling Walls Foundation's “Breakthrough of the Year 2025” award in the Women's Impact category.

Scientists from the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ) have developed an AI model that assesses the long-term individual risk for more than 1,000 diseases. The model, which was trained and tested using anonymized medical data from the UK and Denmark, can predict health events over a period of more than a decade.

Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

A molecular mechanism that contributes to the progression of Alzheimer’s disease has been discovered by a research team of Heidelberg University. The team, using an Alzheimer’s mouse model, demonstrated that a neurotoxic protein-protein complex is responsible for nerve cells in the brain dying off and the resulting cognitive decline. This finding opens up new perspectives for the development of effective treatments.

The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new non-invasive diagnostic method designed by Fraunhofer researchers is set to make it possible to detect this aggressive form of cancer early on with high accuracy, significantly improving the prognosis for treatment.

Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

Researchers from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and ETH Zürich have created the first integrated map detailing the metabolic and molecular changes in human blood stem cells as they age, specialize, or turn cancerous. Their innovative research, made possible by highly sensitive low-input techniques, identifies the nutrient choline, as a key player in preserving youthful stem cell traits.

For his outstanding achievements in his doctorate at the interface between chemistry and biology, Jonas Wilhelm is awarded an Otto Hahn Medal 2025 by the Max Planck Society. He wrote his thesis in the department Chemical Biology of Kai Johnsson at the Max Planck Institute for Medical Research. In his doctorate, Jonas Wilhelm developed a molecular tool, a biosensor that records and permanently stores biological activities at the cellular level.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research.

With the goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In pursuit of the artificial cell, a research team has cleared a crucial hurdle. Using the new RNA origami technique, they succeeded in producing nanotubes that fold into cytoskeleton-like structures.

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.